Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer

Journal of Drug Targeting

Volumn 19, Issue 10, 2011, Pages 859-873

  Nadler Milbauer, Mirela ^a   Apter, Lior ^a   Haupt, Ygal ^b,c,d   Haupt, Sue ^b   Barenholz, Yechezkel ^e   Minko, Tamara ^f   Rubinstein, Abraham ^a,g,h  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e HEBREW UNIVERSITY   (Israel)

^f RUTGERS UNIVERSITY   (United States)

^g RUTGERS UNIVERSITY   (United States)

^h David R Bloom Center of Pharmacy   (United States)

Author keywords

Alginate beads; Colorectal cancer; Doxil; Drug delivery; Nutlin 3; Synchronized release; Synergism

Indexed keywords

CALCIUM ALGINATE; DOXORUBICIN; NUTLIN 3; PHOSPHATE; POLYSACCHARIDE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CECUM; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DEGRADATION; DISPERSION; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ALGINATES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CROSS-LINKING REAGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONIC ACID; HEXURONIC ACIDS; HT29 CELLS; HUMANS; IMIDAZOLES; PIPERAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 81255138300     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2011.622401     Document Type: Article

References (34)

1. Adkin DA, Kenyon CJ, Lerner EI, Landau I, Strauss E, Caron D, Penhasi A, Rubinstein A, Wilding IR. (1997). The use of scintigraphy to provide proof of concept for novel polysaccharide preparations designed for colonic drug delivery. Pharm Res, 14, 103-107. (Pubitemid 27113323)
2. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. (2007). Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene, 26, 3473-3481. (Pubitemid 46816754)
3. Amselem S, Gabizon A, Barenholz Y. (1990). Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci, 79, 1045-1052.
4. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators. (2006). Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med, 355, 885-895. (Pubitemid 44315981)
5. Arnoletti JP, Bland KI. (2006). Neoadjuvant and adjuvant therapy for rectal cancer. Surg Oncol Clin N Am, 15, 147-157. (Pubitemid 43017761)
6. Azab AK, Kleinstern J, Doviner V, Orkin B, Srebnik M, Nissan A, Rubinstein A. (2007). Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I -norcholesterol. J Contr Rel, 123, 116-122. (Pubitemid 47569999)
7. Baluom M, Friedman M, Rubinstein A. (2001). Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. J Control Release, 70, 139-147. (Pubitemid 32144798)
8. Bullock AN, Fersht AR. (2001). Rescuing the function of mutant p53. Nat Rev Cancer, 1, 68-76. (Pubitemid 33741882)
9. Gabizon A, Shmeeda H, Barenholz Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet, 42, 419-436. (Pubitemid 36649037)
10. Hagesaether E, Bye R, Sande SA. (2008). Ex vivo mucoadhesion of different zinc-pectinate hydrogel beads. Int J Pharm, 347, 9-15. (Pubitemid 350180311)
11. Haupt S, Haupt Y. (2006). Importance of p53 for cancer onset and therapy. Anticancer Drugs, 17, 725-732. (Pubitemid 44310170)
12. Haupt S, Zioni T, Gati I, Kleinstern J, Rubinstein A. (2006). Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. Eur J Pharm Sci, 28, 204-211. (Pubitemid 43766100)
13. Hixon A, Crowell J. (1931). Dependent of reaction velocity upon surface and agitation. Ind Eng Chem, 23, 923-931.
14. Horowitz AT, Barenholz Y, Gabizon AA. (1992). In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta, 1109, 203-209.
15. Johnston PG. (2006). Prognostic Markers of Local Relapse in Rectal Cancer: Are We Any Further Forward?. J Clin Oncol 24;4049-4050. (Pubitemid 46622276)
16. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN. (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res, 26, 492-501.
17. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953. (Pubitemid 26398409)
18. Mei X, Etzler FM, Wang Z. (2006). Use of texture analysis to study hydrophilic solvent effects on the mechanical properties of hard gelatin capsules. Int J Pharm, 324, 128-135. (Pubitemid 44528913)
19. Midgley R, Kerr D. (1999). Colorectal cancer. Lancet, 353, 391-399. (Pubitemid 29088178)
20. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev, 56, 185-229. (Pubitemid 38720829)
21. Nadler-Milbauer MA, Azab AK, Kleinstern J, Barenholz Y. Rubinstein A. (2009). In vitro and in vivo analysis of pulsatile biodegradation of mucoadhesive hydrogels. J Drug Del Sci Tech, 19, 247-255.
22. O'Hagan HM, Ljungman M. (2004). Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2. Oncogene, 23, 5505-5512. (Pubitemid 39044061)
23. Peters MC, Isenberg BC, Rowley JA, Mooney DJ. (1998). Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed, 9, 1267-1278. (Pubitemid 28525928)
24. Ravizza R, Gariboldi MB, Passarelli L, Monti E. (2004). Role of the p53/ p21 system in the response of human colon carcinoma cells to Doxorubicin. BMC Cancer, 4, 92.
25. Richardson JC, Dettmar PW, Hampson FC, Melia CD. (2004). A simple, high throughput method for the quantification of sodium alginates on oesophageal mucosa. Eur J Pharm Biopharm, 57, 299-305. (Pubitemid 38283707)
26. Rubinstein A, Nakar D, Sintov A. (1992). Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content. Pharm Res, 9, 276-278.
27. Segal E, Pan H, Ofek P, Udagawa T, Kopecková P, Kopecek J, Satchi-Fainaro R. (2009). Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS ONE, 4, e5233.
28. Shangary S, Wang S. (2009). Small-molecule inhibitors of the MDM2-p53 protein- protein Interaction to reactivate p53 function: a novel approach for cancer therapy. Ann Rev Pharmacol Toxicol, 49, 223-241.
29. Sheng JJ, McNamara DP, Amidon GL. (2009). Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm, 6, 29-39.
30. Storm G, Steerenberg PA, van Borssum Waalkes M, Emmen F, Crommelin DJ. (1988). Potential pitfalls in in vitro antitumor activity testing of free and liposome-entrapped doxorubicin. J Pharm Sci, 77, 823-830. (Pubitemid 19028868)
31. Sun W, Haller DG. (2005). Adjuvant therapy of colon cancer. Semin Oncol, 32, 95-102. (Pubitemid 40250131)
32. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-848. (Pubitemid 38174664)
33. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bünte H. (1995). Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose non-steroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum, 38, 813-830.
34. Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L. (2010). Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol, 136, 1597-1604.